Meibomian Gland
Heat application device offers another option for MGD treatment
Understanding of dry eye has improved dramatically, and we have come to appreciate that optimizing the ocular surface and ensuring the health of the tear films are easily the most important unmet needs in improving patient care and surgical outcomes. This applies not only to routine cataract surgery, but to LASIK and a variety of other ophthalmic surgeries as well.
Wet cheekbones: Is it time to move away from eye drops?
There is this really cool “meeting before the meeting” that occurs on the Thursday of ASCRS and AAO week each year. The Ophthalmology Innovation Summit is the brainchild of Emmett Cunningham, a uveitis specialist who now spends his days nurturing startups. Many of the cutting-edge tech, device and pharma companies that surround our practices come together under the OIS tent to present their latest ideas to an audience that includes various and sundry “masters of the universe” types looking for their next blockbuster investment. Frankly, it is a bit pricey, but if you can sneak away on the day before Subspecialty Day, it is a fascinating look into what may be coming to your office.
Meibomian gland segmentation may precede atrophy
BLOG: Early intervention matters when treating dry eye
AAO plenary session to feature WHO vision report
In-office technology improves ocular surface care
Consider biofilm as alternative theory of dry eye etiology
Eye care professionals know all too well that there have been decades of confusion and complexity surrounding the etiology of dry eye disease. Not only that, but what constitutes dry eye has also been the subject of debate for years. What defines dry eye? How is blepharitis involved? How does aqueous tear deciency, or ATD, relate to meibomian gland dysfunction? Despite our best eorts, our ability to understand the workings of the tear system and how disease affects this system has been limited at best.